A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Clinical trial NCT04702880 · COMPLETED
Trial details
- NCT number
- NCT04702880
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-17
- Primary completion
- 2025-05-22
- Enrollment
- 135
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.